Teclistamab for multiple pulmonary lesions in extramedullary myeloma: first successful case and review of the literature.
A new cancer-fighting antibody showed promise against a rare, aggressive form of myeloma in the lungs, opening a potential treatment avenue for this difficult disease.
This case report describes the first documented use of teclistamab (anti-BCMA × anti-CD3 bispecific antibody) to achieve clinical response in a patient with multiple myeloma presenting as extramedullary disease in the lungs, with an accompanying literature review of bispecific use in EMD. The finding is clinically notable as EMD confers poor prognosis and has limited treatment options, but the single-case design caps evidence quality.
What the study was
- Study design
- Single case report + literature review
- Population
- Single patient with extramedullary multiple myeloma with pulmonary lesions
- Sample size
- 1
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Annals of Hematology
Why it surfaced
Score capped per single-case-report rule (max 4); EMD is high unmet need but single case cannot support clinical conclusions. Teclistamab expanding indications has signal value for downstream literature tracking.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.